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Background: Recent studies have indicated the predominance of Toxoplasma gondii genotype Chinese 1 in
animals in China. However, little is known of the genetic features of the parasite in humans. This study aims to
determine the prevalence of anti-T. gondii antibodies based on which the genetic character of the parasite was
identified in cancer patients in China.
Methods: A total of 1014 serum samples with malignant neoplasms were collected from six tertiary-care hospitals
(HAUCM, APH, HAMU, XAH, FHH and HBMC) from January, 2012 to August, 2013. Antibodies against T. gondii were
examined by enzyme-linked immunosorbent assay (ELISA). Blood samples were subsequently used for PCR assay to
detect T. gondii DNA (gra6). The DNA positive samples were subjected to genotyping using a multiplex multilocus
nested PCR-RFLP at 10 loci, including sag1, sag2, sag3, btub, gra6, l358, c22-8, c29-2, pk1 and apico. Samples from
the patients were anonymous and only data with regard to age and gender was available at sample collection.
Results: Overall, 8.38% (85/1014) of the examined patients showed positive antibodies against T. gondii. Among
them, 61 (6.02%) were seropositive only for IgG, 16 (1.58%) were only for IgM, and 8 (0.79%) were found to be
positive for both IgG and IgM. The seroprevalence of antibodies to Toxoplasma ranged from 5.8% to 11.0%, without
regional difference (χ2 = 4.764, P = 0.445). No significant differences of the positive rates of T. gondii infection were
noted in genders (male, 8.96%; female, 7.45%) (χ2 = 0.707, P = 0.400) and in ages (χ2 = 1.172, P = 0.947). Of 1014 DNA
samples, 36 (3.55%) were positive for T. gondii by nested PCR at gra6 locus and nine gave rise to complete
genotyping results. All samples with achieved PCR-RFLP genotyping showed a common genetic character of type
Chinese 1 (ToxoDB#9).
Conclusion: Seroprevalence of toxoplasmosis in immunosuppressed individuals is rarely reported in China and we
presented a positive rate of 8.38% in cancer patients. Toxoplasma genomic DNA genotyping demonstrated a
common genetic character of Chinese 1, indicating a possible pathogenic origin of animals in human infection.
Keywords: Toxoplasma gondii, Cancer patients, Seroprevalence, Genotyping, China* Correspondence: hkq1510@163.com; shenjilong53@126.com
†Equal contributors
1Clinical Laboratory, the First Affiliated Hospital of Anhui University of
Chinese Medicine, 230031 Hefei, Anhui Province, China
2Department of Parasitology, Provincial Laboratory of Microbiology &
Parasitology and the Key Laboratory of Zoonoses Anhui, Anhui Medical
University, 230032 Hefei, Anhui Province, China
Full list of author information is available at the end of the article
© 2015 Wang et al.; licensee BioMed Central. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Wang et al. Parasites & Vectors  (2015) 8:162 Page 2 of 7Background
Toxoplasma gondii is a worldwide protozoan parasite
that can infect virtually all warm-blooded animals, includ-
ing humans. It is prevalent in most areas of the world and
up to one-third of the human population is chronically in-
fected, with an endemicity from around 10% to 70% and
the prevalence is high in warmer and humid areas [1,2].
Food-borne transmission of T. gondii is considered to be
the most important route for human infection [3,4], which
occurs through the ingestion of raw or inadequately cooked
meat containing tissue cysts, or of food or water contami-
nated by oocysts shed by felids. Moreover, infection ac-
quired during pregnancy can be transmitted to the foetus,
sometimes leading to serious consequences [5]. T. gondii
infection is currently incurable because the parasite can
change from the rapidly replicating tachyzoite stage to the
dormant bradyzoite stage, and the latter is impervious to
host immunity and also to drugs. Toxoplasmosis is fatal in
the immunocompromised individuals such as cancer pa-
tients with chemotherapy, HIV/AIDS patients and organ
transplant recipients [6-8]. Although the infection is usually
believed to be harmless and have a benign course in im-
munocompetent persons, it could be indirectly responsible
for deaths due to its effects on the traffic and workplace ac-
cidents, and also suicides. Moreover, latent toxoplasmosis is
probably one of the most important risk factors for schizo-
phrenia [9]. China is the first-most populous nation in the
world (National Bureau of Statistics 2010) and a high rate
of neoplasmas. Clinical toxoplasmosis in malignant patients
in China is of great public health concern, since it can lead
to the active parasitemia and life-threatening disease due to
the rupture of pre-existent cysts, contributing to worsening
of the clinical condition [10]. Therefore, it becomes essen-
tial to investigate the prevalence and genetic structure of T.
gondii in cancer patients of China.
The frequency of seropositivity of T. gondii varies in dif-
ferent countries or even in different areas of a given coun-
try. Prevalence below 30% was observed in USA, Northern
Europe, and South East Asia [11,12], while above 60% in
the regions of tropical African and Latin America [13,14].
Moreover, T. gondii infection ranges from 8.8% to 37.3% in
women of fertile age in the Indian subcontinent [15], and
from 5.1% to 16.4% in populations of Kyrgyzstan, respect-
ively [16]. Walle et al. [7] from Ethiopia reported the posi-
tive rates of 87.4% and 10.7% of anti-Toxoplasma IgG and
IgM, respectively. Previous investigation in Brazil indicated
that toxoplasmic encephalitis might reach up to 40% in pa-
tients with AIDS, among them 10-30% died [17]. However,
little is known in the scientific community about the epi-
demiology of T. gondii and the parasite genotypes in human
populations and, particularly, in cancer patients of China.
The genetic diversity of T. gondii varies in different geo-
graphical regions and hosts. In North America and Europe,
T. gondii is highly clonal and consists of three distinctlineages (types I, II and III). Type I strains are highly viru-
lent to mice. The type II and III lineages are widespread
throughout all continents and dominate in North America,
Europe and Africa, meanwhile, type II strains are the most
prevalent cause of human toxoplasmosis in both congenital
infection and AIDS patients in North America and Europe
[18-20]. In contrast, genetic characterization of isolates
from human patients and animals in South America are
genetically and biologically diverse [21], and severe toxo-
plasmosis in immunocompetent human patients is often
associated with atypical genotypes [22]. We have previously
identified limited genotypes of isolates from stray cats, pigs,
sheep and chickens in China, and genotype ToxoDB#9
(termed as Chinese 1) is widespread and is likely the major
T. gondii lineage circulating in animals and humans in
China [23,24]. So far, neither detailed information on ser-
oepidemiology of Toxoplasma in immunocompromised
patients nor precise approaches concerning the genetic fea-
tures of T. gondii isolates from humans have been uncov-
ered in China. Genotyping studies of T. gondii in cancer
patients may help reevaluate the population genetic struc-
ture, population biology and pathogenesis of this important
zoonotic pathogen in China.
Herewith we examined the seroprevalence of anti-T. gon-
dii antibodies, as well as the population structure of this
parasite in cancer patients, and hope to provide baseline
data for the implementation of effective strategies for the
control and prevention of T. gondii infection in China.
Methods
Ethical aspects
This study was approved by the Institutional Review
Board (IRB) of the Institute of Biomedicine at Anhui
Medical University (Approval No: 2012012). Participa-
tion in the study was voluntary without incentives. Both
studies were carried out in accordance with good clinical
practices; the purpose and procedures of the study were
explained to all participants, and a written informed
consent was obtained from each participating patient.
Participants and serum sample preparation
A total of 1014 inpatients and outpatients were enrolled in
the study from 6 representative tertiary-care hospitals (The
First Hospital of Anhui University of Chinese Medicine
(HAUCM), Anhui Provincial Hospital (APH), the First
Hospital of Anhui Medical University (HAMU), Xinan
Hospital (XAH), the First Hospital of Hefei (FHH) and the
First Hospital of Bengbu Medical College (HBMC)) in
Anhui province, Eastern China, from May 2012 to August
2013. One sample from each patient was collected and the
information such as gender and age were also obtained
and matched. Approximately 5 ml of venous blood sam-
ples were drawn from each patient with informed consent.
All the blood samples were labeled individually and cooled
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transport to the laboratory. Blood samples were centri-
fuged and sera were recovered and transferred to 1.5 ml
centrifuge tubes. The serum samples were stored at −80°C
until tested for T. gondii antibodies.
Immunological test for T. gondii antibodies
All serum samples were analyzed by qualitative and quanti-
tative methods for anti-Toxoplasma IgG and IgM anti-
bodies by enzyme-linked immunosorbent assay (ELISA)
kits commercially available (Haitai Biological Pharmaceuti-
cals Co., Ltd, Zhuhai, China), following the manufacturer’s
instructions. Positive, negative, critical and blank controls
supplied with the kit were included in each testing plate. In
brief, sera diluted 1:100 were incubated in a T. gondii
antigen-coated 96-well plate at 37°C for 30 min, and the
plate was washed five times, then a drop of diluted HRP-
labelled conjugate was added to each well. After a final
washing, “A” and “B” solutions were added that are avail-
able in the kit and incubated at 37°C for 15 min. The op-
tical density (OD) values of the test sera were corrected
according to blank controls, and OD values were read
using an automated microplate reader (Bio-Tek, Vermont,
USA). The threshold value was determined by the mean of
3 critical controls in each test. A result equal to or greater
than threshold values was considered positive.
DNA extraction and Toxoplasma gra6 amplification
Genomic DNA was extracted from the whole blood sam-
ples using the QIAamp Mini DNA kit (Qiagen, Hilden,
Germany) according to the manufacturer’s instructions.
The DNA samples were tested by nested PCR of the GRA6
gene. Briefly, 1.5 μl of DNA template was add to a final vol-
ume of 25 μl PCR mixture consisting of 12.5 μl PCR Premix
Taq (TaKaRa, Dalian, China), and 1.5 μl of each of the outer
primers. The amplification steps included a first cycle of de-
naturation at 94°C for 5 min, 35 cycles of denaturation at
94°C for 30 s, annealing at 55°C for 60 s, and extension at
72°C for 90 s, and a final extension step at 72°C for 10 min.
The resulting products were diluted with equal an volume
of nuclease-free water and then used as template for the
nested PCR with inner primers in a total volume of 25 μl
under the similar program. Each PCR set included a posi-
tive control of DNA extracted from T. gondii RH strain and
a negative control of nuclease-free water. The PCR-
generated products and molecular weight markers were
subjected to electrophoresis on a 1.5% agarose gel, stained
with ethidium bromide, and visualized under UV transillu-
minator (Hema, Zhuhai, China).
Genetic characterization of T. gondii in positive DNA
samples
DNA samples that were positive for gra6 were subse-
quently genotyped by multi-locus PCR-RFLP using thegenetic loci sag1, sag2, sag3, btub, gra6, c22-8, c29-2, l358,
pk1 and apico [25]. Briefly, pre-amplification was carried
out using a set of mixed outer primers in a single reaction.
Then, multiplex PCR-amplified products were diluted 1:1
with deionized water, and then used for nested PCR ampli-
fications with inner primers for each locus, respectively.
Eight genotype references of T. gondii strains were set up
as positive controls including GT1, PTG, CTG, MAS,
TgCatBr5, TgCatBr64, TgCgCa1 and TgRsCr1. For each
locus, the PCR mixture consisted of 12.5 μl PCR Premix
Taq (TaKaRa, Dalian, China), 1 μl 10 μm forward and re-
verse primers, and 1.5 μl PCR-generated products in a
25 μl reaction volume. All reaction mixtures were made up
to 25 μl with deionized water. The nested PCR was carried
out with an annealing temperature at 60°C for 60s for all
the loci. The products were digested using restriction en-
donucleases (Fermentas, Vilnius, Lithuania) specific for
each genetic marker according to the manufacturer’s in-
structions. The restriction fragments were visualized by
electrophoresis using a 2.5%-3% agarose gel stained with
ethidium bromide and photographed using a gel documen-
tation system (Hema, Zhuhai, China).Data analysis
Pearson Chi-Square and Fisher’s exact tests were used to
investigate associations among qualitative categorical
variables using SPSS (SPSS Inc., Chicago, Illinois). All
tests were 2-sided, and the level of significant difference
was defined as P < 0.05.Results
Frequency of anti-Toxoplasma IgG and IgM antibodies
Data on 1014 cancer patients in age range of 27 to
91 years from six tertiary-care hospitals of Anhui prov-
ince are presented in Tables 1, 2 and 3. The mean age of
the participants was 57.44 ± 12.80 years old. Males con-
stituted 61.6% and females accounted for 38.4%. Anti T.
gondii antibodies were detectable in sera of 85 out of
1014 cases, with an overall seroprevalence of 8.38%.
Among them, 61 (6.02%) patients were seropositive for
only IgG, 16 (1.58%) for only IgM, and 8 (0.79%) for
both IgG and IgM, with a distribution of 5.8% (6/103) in
HAUCM, 11.0% (33/299) in APH, 6.6% (4/61) in
HAMU, 6.0% (5/83) in XAH, 8.9% (8/90) in FHH, and 7.7%
(29/378) in HBMC, respectively. No significant difference
of positive rates were found in hospitals (χ2 = 4.764,
P = 0.445), or in age groups (χ2 = 1.172, P = 0.947), or in
gender (χ2 = 0.707, P = 0.400) (Tables 1 and 2).
The frequencies of IgG antibodies against T. gondii are
presented in Table 3, and no statistically significant differ-
ence was seen among the cancers (χ2 = 16.675, P = 0.781).
Additionally, the positive rate of Toxo-IgM antibodies was
the highest in intracranial tumors (7.69%), followed by
Table 1 Age-associated seroprevalence of T. gondii infection in cancer patients of 6 representative hospitals*




0-39 4 28 2 8 7 23 5/72 6.9
40-49 19 73 12 27 17 82 18/230 7.8
50-59 21 68 15 12 21 94 19/231 8.2
60-69 35 78 16 30 29 103 25/291 8.6
70-79 20 43 13 3 15 65 14/159 8.8
≥80 4 9 3 3 1 11 4/31 12.9
Total 103 299 61 83 90 378 85/1014 8.38
*χ2 = 1.172, p = 0.947.
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cinoma (1.45%).Multilocus PCR-RFLP genotyping of T. gondii isolates
Of the 1014 DNA samples investigated, 36 (3.55%) were
positive for T. gondii gra6 by PCR, including 3 from lung
cancer, 3 from gastric carcinoma, 3 from rectal carcinoma,
1 from lymphoma, 18 from hepatocellular carcinoma, 5
from cervical cancer, 1 from oesophageal carcinoma, 1 from
nasopharyngeal carcinoma, and 1 from osteosarcoma, dis-
tributed in 24 (2.37%) IgG-positive and 12 (1.18%) IgG-
negative patients.
Nine of the 36 gra6 positive samples showed complete
genotyping results, among them 7 from hepatocellular car-
cinoma and 2 from cervical cancer. Only one pattern of type
Chinese 1 (ToxoDB#9) was identified in the 9 samples. The
electrophoresis exhibited type II pattern at sag2, gra6, l358,
pk1 and c22-8, but type III pattern at c29-2, sag3, and btub
loci and type I pattern at the apico locus. The results of
genotyping of Toxoplasma genomic DNA from humans and
8 reference strains were illustrated in Table 4 and Figure 1.Table 3 The rates of positivity of T. gondii IgG and IgM
antibodies in different cancer patients*






Lung cancer 102 7 (6.86) 3 (2.94)
Gastric carcinoma 110 6 (5.45) 2 (1.82)
Rectal carcinoma 119 8 (6.72) 2 (1.68)
Intracranial tumor 13 1 (7.69) 1 (7.69)
Lymphoma 21 1 (4.76) 1 (4.76)
Breast carcinoma 56 1 (1.79) 2 (3.57)
Hepatocellular carcinoma 220 24 (10.91) 8 (3.64)Discussion
The human seroprevalence of Toxoplasma infection is high
across the world, with obvious geographical variation [26].
The majority of studies emerging from Latin American
countries show significantly high rates of seropositivity, most
of which had a prevalence above 60% [14]. Frequent infec-
tions are noted in Brazil from a study in pregnant women
showing a prevalence of 65.1%-68.9% [27]. However, human
toxoplasmosis in the United States is significantly decreased,
according to the two most recent NHANES (NationalTable 2 Prevalence of antibodies to T. gondii in cancer
patients by gender in Eastern China*
Gender No. examined No. positive Prevalence (%)
Male 625 56 8.96
Female 389 29 7.45
Total 1014 85 8.38
*χ2 = 0.707, p = 0.400.Health and Nutrition Examination Survey) studies, ranging
from 22.5% to 12.4% [28,29]. Additionally, Rai et al. [30] re-
ported a higher seroprevalence of T. gondii infection (68.7%)
in Nepalese cancer patients than in those with ocular or
other diseases. Similarly, high frequency of T. gondii infec-
tion has been detected among immunocompromised pa-
tients especially in those suffering from malignancy in Egypt
and Korea [31,32]. In the present study, 8.38% (85/1014) of
the 1014 cancer patients were seropositive for T. gondii
tested by ELISA, which is relatively low compared with re-
ports from other countries [33], and similar to the investiga-
tion in pregnant women of China, within the range of
0-10% [8]. The seroprevalence in humans varies in regions
possibly due to the geographical factors, eating habits, pet-
keeping and management, as well as differences in livestock
farming practices. T. gondii prevalence in China was re-
ported to be 5.2% during 1988–1992 but increased to 7.9%
during 2001–2004 in two separate nationwide surveys [34],
suggesting that toxoplasmosis may constitute a serious
health problem in China.Cervical cancer 80 9 (11.25) 2 (2.50)
Carcinoma of pancreas 23 1 (4.35) 0
Esophageal carcinoma 120 6 (5.00) 2 (1.67)
Nasopharyngeal carcinoma 69 3 (4.35) 1 (1.45)
Prostatic carcinoma 13 1 (7.69) 0
Osteosarcoma 12 1 (8.33) 0
*χ2 = 16.675, p = 0.781.
Table 4 T. gondii genotypes identified in blood of PCR positive cancer patients
Isolate ID Host SAG1 SAG2 SAG3 BTUB GRA6 c22-8 c29-2 L358 PK1 Apico Genotype
GT1 Goat I I I I I I I I I I Reference, Type I, ToxoDB#10
PTG Sheep II/III II II II II II II II II II Reference, Type II, ToxoDB#1
CTG Cat II/III III III III III III III III III III Reference, Type III, ToxoDB#2
TgCgCa1 Cougar Ι II III II II II μ-1a Ι μ-2a Ι Reference, ToxoDB#66
MAS Human μ-1a II III III III μ-1a Ι Ι III Ι Reference, ToxoDB#17
TgCatBr5 Cat Ι III III III III Ι Ι Ι μ-1a Ι Reference, ToxoDB#19
TgCatBr64 Cat Ι μ-1a III III III μ-1a Ι III III Ι Reference, ToxoDB#111
TgRsCr1 Toucan μ-1a II III Ι III μ-2a Ι Ι III Ι Reference, ToxoDB#52
TgHuCn1, 2, 3, 4, 5, 6, 7, 8, 9 Human μ-1a II III III II II III II II Ι Chinese 1, ToxoDB#9
aμ-1 and μ-2 represent unique RFLP genotypes, respectively.
Figure 1 Representative gel image of RFLP genotyping (markers SAG1, BTUB, GRA6 and L358). Sample IDs are at the top of the gel
images, genotype results are at the bottom. GT1, PTG, CTG, Ca1 (TgCgCa1), MAS, Br5 (TgCatBr5), Br64 (TgCatBr64) and Cr1 (TgRsCr1) are reference
strains. Cn1: TgHuCn1; Cn2: TgHuCn2; Cn3: TgHuCn3; Cn4: TgHuCn4; Cn5: TgHuCn5; Cn6: TgHuCn6; Cn7: TgHuCn7; Cn8: TgHuCn8; Cn9: TgHuCn9.
MK: molecular markers.
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ence in infection rates among malignancies, which dif-
fers to that reported in the previous investigation in
China [6]. The high seroprevalence in cancer patients in-
dicates a considerable risk due to the fact that the
underlying latent Toxoplasma infection may be activated
following long term chemotherapy leading to the com-
promised immunity of the patients. Obviously, a com-
parative study is needed to demonstrate the association
of Toxoplasma infection with pathological sources of tu-
mors and duration of chemotherapy.
In the present study, a total of 85 patients were found to
be positive for antibodies against T. gondii (8.38%), which
corresponds to 7.9% prevalence previously surveyed in the
general Chinese population [35]. These results revealed
that the frequency of Toxoplasma infection in a general
hospital-based study was similar to that in a community-
based study. We noted that Toxoplasma infection in malig-
nant patients does not seem to increase progressively with
age, which is similar to that shown with a previous study
[33] but is in disagreement with the report from the United
States [28]. The difference in target population surveyed
may account for the varied results.
Genotyping of Toxoplasma isolates in humans is rela-
tively rare due to the transient nature of parasitaemia. In
toxoplasmosis, the initial dissemination of tachyzoites is
usually limited to less than 20 day’s duration but this may
vary according to the genotype of infected parasite and the
host immune response [2]. The ability to detect T. gondii
genomic DNA in clinical samples made it possible to dir-
ectly type the infecting isolate obviating the need to harvest
the parasite [36]. A nested PCR with its double amplifica-
tion steps was used to improve the diagnostic yield and to
allow for subsequent assessment of T. gondii genotypes.
However, a low positive rate was found among the patients
with no correlation to their serological profile. In agreement
with the present results, Messaritakis et al. [37] tried to
amplify gra6 from clinical samples of 290 acutely infected
patients and reported positive finding in only 3.12%. Since
the primary objective of the present study was genotyping,
GRA6 gene was selected in view of its higher polymorph-
ism than other described markers. Understanding T. gondii
population structure is of great interest, as it may provide
us with essential information regarding the transmission
and evolution of this widespread zoonotic parasite, and its
pathogenesis as well. Based on 10 PCR-RFLP markers, the
genetic variability of T. gondii isolates from China has been
revealed gradually. A total of 10 genotypes were identified,
indicating limited diversity of the parasite in China, which
is in sharp contrast to South America where a variety of
parasite lineages are transmitted in the environment [22].
It is reported that strain genotype has been associated
with clinical severity of human toxoplasmosis [38]. Type II
strains have been shown to be most prevalent in congenitalinfection and AIDS patients in North America and Europe
[20,39]. In our study, only one pattern of genotype Chinese
1 (ToxoDB#9) was identified, which has been found to be
widely and predominantly distributed in animal hosts such
as cats, pigs, and voles in a frequency of 73.9% in China
[23,40]. Our results showed that Toxopasma DNAs of all 9
samples share the genetic pattern of type Chinese 1, which
strongly suggests the pathogenic origin of human infection
from animal hosts. Type Chinese1 has also been identified
from Sri Lanka, Colombia, Brazil and the United States,
suggesting that it might be widespread from Asia to North
and South America [24]. Obviously, more studies should
be carried out for deep insight into the population genetic
structure of T. gondii isolates and the clinical manifesta-
tions of patients and for providing useful information for
control and prevention of human toxoplasmosis. To our
knowledge, this is the first report of genetic typing of T.
gondii from cancer patients in China.
Conclusion
The 8.38% seropositive rate of Toxoplasma infection in
Anhui province coincides with the overall prevalence in
China, which is relatively low compared with that in other
parts of the world. The genetic feature of Toxoplasma iso-
lates found in cancer patients corroborates the findings of
previous studies that T. gondii has a limited diversity in
China. Studies on a larger number of samples from differ-
ent nationalities are imperative for better understanding of
the parasite genetic structure and transmission of T. gondii
in China.
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